vs

Side-by-side financial comparison of La Rosa Holdings Corp. (LRHC) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

La Rosa Holdings Corp. is the larger business by last-quarter revenue ($20.2M vs $12.5M, roughly 1.6× Avidity Biosciences, Inc.). La Rosa Holdings Corp. runs the higher net margin — -27.4% vs -1398.3%, a 1371.0% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 3.2%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 72.5%).

V. La Rosa and Sons Macaroni Company was founded in 1914 by Vincenzo La Rosa, a Sicilian immigrant. The company eventually became one of the largest regional brands in the United States producing over 40 varieties of pasta.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

LRHC vs RNA — Head-to-Head

Bigger by revenue
LRHC
LRHC
1.6× larger
LRHC
$20.2M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+430.9% gap
RNA
434.0%
3.2%
LRHC
Higher net margin
LRHC
LRHC
1371.0% more per $
LRHC
-27.4%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
72.5%
LRHC

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
LRHC
LRHC
RNA
RNA
Revenue
$20.2M
$12.5M
Net Profit
$-5.5M
$-174.4M
Gross Margin
8.4%
Operating Margin
-24.7%
-1513.5%
Net Margin
-27.4%
-1398.3%
Revenue YoY
3.2%
434.0%
Net Profit YoY
-125.7%
-117.0%
EPS (diluted)
$-5.44
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LRHC
LRHC
RNA
RNA
Q3 25
$20.2M
$12.5M
Q2 25
$23.2M
$3.8M
Q1 25
$17.5M
$1.6M
Q4 24
$17.7M
$3.0M
Q3 24
$19.6M
$2.3M
Q2 24
$19.1M
$2.0M
Q1 24
$13.1M
$3.5M
Q4 23
$2.2M
Net Profit
LRHC
LRHC
RNA
RNA
Q3 25
$-5.5M
$-174.4M
Q2 25
$78.4M
$-157.3M
Q1 25
$-95.7M
$-115.8M
Q4 24
$-5.1M
$-102.3M
Q3 24
$-2.5M
$-80.4M
Q2 24
$-2.3M
$-70.8M
Q1 24
$-4.6M
$-68.9M
Q4 23
$-60.4M
Gross Margin
LRHC
LRHC
RNA
RNA
Q3 25
8.4%
Q2 25
8.0%
Q1 25
8.8%
Q4 24
8.9%
Q3 24
8.3%
Q2 24
8.3%
Q1 24
8.9%
Q4 23
Operating Margin
LRHC
LRHC
RNA
RNA
Q3 25
-24.7%
-1513.5%
Q2 25
-10.6%
-4448.7%
Q1 25
-26.7%
-8360.9%
Q4 24
-17.1%
-4069.6%
Q3 24
-8.9%
-4200.9%
Q2 24
-9.7%
-4040.4%
Q1 24
-35.0%
-2178.6%
Q4 23
-3043.5%
Net Margin
LRHC
LRHC
RNA
RNA
Q3 25
-27.4%
-1398.3%
Q2 25
337.8%
-4089.3%
Q1 25
-546.5%
-7360.0%
Q4 24
-28.7%
-3439.5%
Q3 24
-12.5%
-3441.7%
Q2 24
-12.2%
-3461.8%
Q1 24
-35.1%
-1943.4%
Q4 23
-2756.2%
EPS (diluted)
LRHC
LRHC
RNA
RNA
Q3 25
$-5.44
$-1.27
Q2 25
$15.25
$-1.21
Q1 25
$-5.86
$-0.90
Q4 24
$28.54
$-0.80
Q3 24
$-16.49
$-0.65
Q2 24
$-12.49
$-0.65
Q1 24
$-0.35
$-0.79
Q4 23
$-0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LRHC
LRHC
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$4.0M
$350.2M
Total DebtLower is stronger
$642.8K
Stockholders' EquityBook value
$1.6M
$1.9B
Total Assets
$21.7M
$2.1B
Debt / EquityLower = less leverage
0.41×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LRHC
LRHC
RNA
RNA
Q3 25
$4.0M
$350.2M
Q2 25
$5.1M
$243.9M
Q1 25
$2.9M
$254.2M
Q4 24
$1.4M
$219.9M
Q3 24
$1.8M
$370.2M
Q2 24
$1.6M
$575.8M
Q1 24
$1.1M
$471.4M
Q4 23
$185.1M
Total Debt
LRHC
LRHC
RNA
RNA
Q3 25
$642.8K
Q2 25
$644.3K
Q1 25
$645.9K
Q4 24
$647.6K
Q3 24
$649.2K
Q2 24
$650.8K
Q1 24
$652.4K
Q4 23
Stockholders' Equity
LRHC
LRHC
RNA
RNA
Q3 25
$1.6M
$1.9B
Q2 25
$3.4M
$1.2B
Q1 25
$-87.5M
$1.3B
Q4 24
$2.6M
$1.4B
Q3 24
$5.0M
$1.5B
Q2 24
$4.7M
$1.2B
Q1 24
$5.6M
$830.9M
Q4 23
$500.8M
Total Assets
LRHC
LRHC
RNA
RNA
Q3 25
$21.7M
$2.1B
Q2 25
$22.9M
$1.4B
Q1 25
$21.0M
$1.5B
Q4 24
$19.4M
$1.6B
Q3 24
$19.7M
$1.6B
Q2 24
$18.7M
$1.3B
Q1 24
$16.3M
$951.5M
Q4 23
$628.6M
Debt / Equity
LRHC
LRHC
RNA
RNA
Q3 25
0.41×
Q2 25
0.19×
Q1 25
Q4 24
0.25×
Q3 24
0.13×
Q2 24
0.14×
Q1 24
0.12×
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LRHC
LRHC
RNA
RNA
Operating Cash FlowLast quarter
$-1.3M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LRHC
LRHC
RNA
RNA
Q3 25
$-1.3M
$-156.2M
Q2 25
$-1.4M
$-199.7M
Q1 25
$-3.5M
$-124.8M
Q4 24
$-1.1M
$-99.9M
Q3 24
$-591.6K
$-65.6M
Q2 24
$-803.1K
$-65.0M
Q1 24
$-538.3K
$-70.4M
Q4 23
$16.5M
Free Cash Flow
LRHC
LRHC
RNA
RNA
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
Q4 23
$15.6M
FCF Margin
LRHC
LRHC
RNA
RNA
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Q4 23
713.1%
Capex Intensity
LRHC
LRHC
RNA
RNA
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Q4 23
39.4%
Cash Conversion
LRHC
LRHC
RNA
RNA
Q3 25
Q2 25
-0.02×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LRHC
LRHC

Real Estate Residential Brokerage Services$16.8M83%
Transferred Over Time$3.5M17%

RNA
RNA

Segment breakdown not available.

Related Comparisons